12.47 -0.19 (-1.50%)
Before hours: 7:20AM EDT
|Bid||12.43 x 3200|
|Ask||12.47 x 1800|
|Day's range||12.01 - 12.74|
|52-week range||6.07 - 13.76|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||3,165.00|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||11.64|
Teva beats estimates for earnings while missing the same for sales in second-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.
Teva Pharmaceutical Industries' <TEVA.TA> quarterly profit beat estimates by two cents and the company reaffirmed its outlook for 2020 despite uncertainty generated by the COVID-19 crisis. The company also released with Regeneron Pharmaceuticals <REGN.O> results for advanced trials for pain medication fasinumab. Teva CEO Kare Schultz said the companies were still waiting for more safety data.
Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates. This strategic partnership combines Teva’s long-standing commercial presence and extensive infrastructure in the U.S. market with Alvotech’s scientific experience and state-of-the-art biologics manufacturing. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.